<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="562">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05153837</url>
  </required_header>
  <id_info>
    <org_study_id>PI2019_843_0064</org_study_id>
    <nct_id>NCT05153837</nct_id>
  </id_info>
  <brief_title>Effect of Oral Water in Healthy Volunteers on Cardiac Output, Regional Flow and Microcirculation in Healthy Volunteers</brief_title>
  <acronym>WATERNAL</acronym>
  <official_title>Effect of Oral Water in Healthy Volunteers on Cardiac Output, Regional Flow and Microcirculation in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Human digestive system physiologically ensures the absorption of oral water and hydration of&#xD;
      the human body. Water is quickly absorbed by the digestive tract with a peak between 15 and&#xD;
      20 minutes. It has demonstrated that oral water remains the best hydration solution that have&#xD;
      an effect on plasma volume expansion and cardiovascular system during exercise. While the&#xD;
      cardiovascular effect of fluid expansion by saline serum is well known (venous return,&#xD;
      preload and cardiac output), effect of oral water varies in the literature depending on the&#xD;
      physiological state of the patient and the clinical state. Thus, the investigators aim to&#xD;
      investigate oral water effects on fluid responsiveness, regional blood flow and&#xD;
      microcirculatory changes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 30, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of fluid responders 30 minutes after fluid expansion</measure>
    <time_frame>30 minutes after fluid expansion</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Intravenous Fluids</condition>
  <condition>Pharmacodynamics</condition>
  <condition>Fluid Therapy</condition>
  <condition>Fluid Responsiveness</condition>
  <condition>Fluid Challenge</condition>
  <arm_group>
    <arm_group_label>oral water</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental group: oral administration of 500 ml of water.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intravenous</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active comparator: Administration of 500 mL of saline (NaCl 0.9%) administered by the venous route</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>saline intravenous administration</intervention_name>
    <description>Administration of 500 mL of saline (NaCl 0.9%) administered by the venous route</description>
    <arm_group_label>intravenous</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>oral water</intervention_name>
    <description>500 ml oral water</description>
    <arm_group_label>oral water</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy volunteer subject between 18 and 30 years old&#xD;
&#xD;
          -  patient with a regular sinus rhythm&#xD;
&#xD;
          -  Echogenic subject.&#xD;
&#xD;
          -  Fasting of solid and liquid since 8 h&#xD;
&#xD;
          -  Subject in regular sinus rhythm.&#xD;
&#xD;
          -  Written consent signed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any known cardiac, renal or endocrine pathology.&#xD;
&#xD;
          -  Arrhythmia rhythm disorder by atrial fibrillation&#xD;
&#xD;
          -  Pregnant or nursing woman.&#xD;
&#xD;
          -  Pathology versus indicating Nacl administration.&#xD;
&#xD;
          -  Person under tutors or curators or deprived of liberty.&#xD;
&#xD;
          -  Person not affiliated to a social security scheme.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pierre Huette, MD</last_name>
    <phone>03.22.08.78.99</phone>
    <email>huette.pierre@chu-amiens.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Amiens-Picardie</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Huette, MD</last_name>
      <phone>03 22 08 78 99</phone>
      <email>huette.pierre@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Christophe BEYLS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Osama ABOU ARAB, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mathieu GUILBART, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yazine MAHJOUB, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 30, 2021</study_first_submitted>
  <study_first_submitted_qc>November 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2021</study_first_posted>
  <last_update_submitted>November 30, 2021</last_update_submitted>
  <last_update_submitted_qc>November 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>intravenous fluids</keyword>
  <keyword>pharmacodynamics</keyword>
  <keyword>fluid therapy</keyword>
  <keyword>fluid responsiveness</keyword>
  <keyword>fluid challenge</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

